12/23/2013 7:34:40 AM
The Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA) decided on Friday to defer a decision on Laquinimod, an oral treatment for relapsing-remitting multiple sclerosis (RRMS). Laquinimod is being developed jointly by Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) and Swedish company Active Biotech. According to Active Biotech, the EMA will issue an opinion at its January, 2014 meeting. Press reports overseas state that the EMA spokesperson refused to provide further details, but said that the agency's experts were entitled to decide on a postponement of a decision of this kind if they saw a necessity to do so.
Help employers find you! Check out all the jobs and post your resume.
comments powered by